이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pacira BioSciences 배당금

배당금 기준 확인 0/6

Pacira BioSciences 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	US$1.51
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PCRX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PCRX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Pacira BioSciences 시장 대비 배당 수익률

PCRX 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PCRX)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Pharmaceuticals)	2.2%
3년 후 애널리스트 예측 (PCRX)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PCRX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PCRX 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PCRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: PCRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Pacira BioSciences 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales

Pacira BioSciences Q2 2022 Earnings Preview

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Pacira BioSciences sees Q2 revenue below consensus

Chief Clinical Officer recently sold US$53k worth of stock

Chief Technical Officer exercised options to buy US$322k worth of stock.

Investor sentiment deteriorated over the past week

Chairman & CEO recently sold US$734k worth of stock

Chief Clinical Officer exercised options to buy US$129k worth of stock.

Independent Director recently sold US$59k worth of stock

Consensus EPS estimates fall by 28%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman & CEO exercised options to buy US$1.5m worth of stock.

President of Rest of World exercised options and sold US$861k worth of stock

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022

President of Rest of World exercised options and sold US$861k worth of stock

Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022